在大鼠中治疗肥胖引起的喘时使用和形式醇治疗
Rania T Ibrahim1, Yasser M Moustafa2,3, Maha Abdullah Alwaili4
1Department of Scientific Research, Egypt Healthcare Authority, Ismailia, Egypt.
Frontiers in pharmacology
|April 17, 2025
概括
结合和formoterol疗法显著改善了大鼠的肥胖引起的喘. 这种双重治疗减少了体重,改善了脂质概况,并恢复了肺组织,为相关的代谢和炎症条件提供了有前途的策略.
科学领域:
- 代谢和炎症性疾病
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是喘发育和严重性的重要危险因素.
- 脂肪积累影响喘病原,需要针对性的治疗策略.
- 肥胖引起的喘带来了复杂的代谢和炎症挑战.
研究的目的:
- 调查单独和组合使用的和formoterol对改善肥胖引起的喘的疗效.
- 评估这些治疗对脂质样本,炎症标志物和肺组织完整性的影响.
- 为了确定双重目标疗法是否可以有效地管理肥胖和喘的相互关联状况.
主要方法:
- 使用高脂肪饮食和卵蛋白敏感化/挑战,建立了肥胖诱导喘的Wistar大鼠模型.
- 动物被分为接受控制饮食,高脂肪饮食或高脂肪饮食与喘诱导的组,然后用formoterol,或两者一起接受治疗的组.
- 关键的结果包括体重,脂质样本 (LDL,HDL,甘油三),炎症指标 (IL-1β,IL-17α) 和肺组织的组织病理分析.
主要成果:
- 结合和形式醇疗法显著降低了体重,改善了脂质样本 (降低了LDL和甘油三,增加了HDL).
- 组合治疗使肺组织结构正常化,并显著减少炎症标记物IL-1β和IL-17α.
- 组织病理学检查证实了组合疗法组的肺组织的恢复.
结论:
- 结合和形式醇疗法为治疗肥胖引起的喘提供了一个有前途的双重作用策略.
- 这种方法有效地准了导致疾病的代谢和炎症成分.
- 通过综合疗法解决肥胖和喘的相互联系性质具有显著的治疗潜力.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
148
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
148
01:26COPD: Management Using Bronchodilators and Corticosteroids
123
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
123
01:17Drugs Used in Lower Respiratory Disorders: Overview
246
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
246
01:23Inhaled Medications
199
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
199